

Lymphomas Understanding the Disease, Mechanisms, Therapies, and Challenges

Enukonda Venkatesh¹, Priyanka Kadari^{2*}, Eliz Joseph^{3*} and Keerthi Chandana Amudala⁴

¹KonaSeema Institute of Medical Sciences & Research Foundation, Amalapuram, Andhra Pradesh, India

²MediCiti Institute of Medical Sciences, Ghanpur, Telangana, India

³West China Medical Center, Sichuan, China

⁴Sri Venkateswara Medical College, Tirupati, Andhra Pradesh, India

Abstract

Lymphoma is a diverse group of hematologic cancers that affect the lymphatic system, with subtypes categorized into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), each with distinct biological characteristics and treatment challenges. Diagnosis often involves complex and time-consuming processes, including biopsy, histopathology, and molecular testing. Despite advances in therapeutic approaches, including chemotherapy, immunotherapy, and stem cell transplants, treatment resistance, relapse, and the variability in treatment response among lymphoma subtypes present ongoing challenges. The lack of early detection methods and the high risk of toxicity associated with conventional therapies further complicate lymphoma management. Future prospects for lymphoma treatment focus on personalized medicine and targeted therapies, with ongoing research exploring novel immunotherapies, precision diagnostics, and innovative treatment combinations. New technologies, such as liquid biopsies and artificial intelligence (AI) driven imaging, aim to improve early detection and optimize treatment plans. Furthermore, the collaboration between international researchers, clinicians, and pharmaceutical companies holds promise for faster development and global access to cutting-edge therapies. The continued evolution of lymphoma treatment, coupled with advancements in diagnostic techniques, is expected to significantly improve patient outcomes and quality of life in the coming years.

Keywords: Lymphoma, Immunotherapy, Diagnosis, Precision medicine, Chemotherapy, Targeted therapies

***Correspondence to:** Priyanka Kadari and Eliz Joseph, MediCiti Institute of Medical Sciences, Ghanpur, Telangana, India and West China Medical Center, Sichuan, China.

Citation: Venkatesh E, Kadari P, Joseph E, Amudala KC (2025) Lymphomas Understanding the Disease, Mechanisms, Therapies, and Challenges. *J Clin Oncol Ther*, Volume 7:1. 142. DOI: <https://doi.org/10.47275/2690-5663-142>

Received: December 29, 2024; **Accepted:** March 26, 2025; **Published:** March 31, 2025

Introduction

Lymphomas are cancers that originate in the lymphatic system, an essential part of the immune system responsible for fighting infections and maintaining fluid balance in the body. The disease occurs when lymphocytes, a type of white blood cell, grow uncontrollably and form tumors in lymph nodes, spleen, bone marrow, or other organs. Lymphomas are broadly categorized into two main types: HL and NHL, with NHL being more common. While both types share some characteristics, they differ in their cellular origins, patterns of spread, and treatment approaches. HL is marked by the presence of Reed-Sternberg cells, which are large, abnormal lymphocytes, whereas NHL encompasses a diverse group of cancers [1-3].

Lymphoma is one of the most common cancers worldwide, accounting for approximately 4% of all cancer cases. According to recent global cancer statistics (2022), there are nearly 553,389 new cases of NHL and 82,469 cases of HL diagnosed annually, with NHL showing higher prevalence in older adults and HL being more common among young adults and adolescents. Survival rates vary based on the subtype and stage at diagnosis. For instance, the five-year survival rate for HL exceeds 88% due to advancements in treatments, while NHL shows a broader range of survival rates depending on its specific subtype.

Lymphomas are slightly more prevalent in males than females [4].

Scientific research has revealed that the development of lymphoma is influenced by genetic, environmental, and immunological factors. Genetic mutations in lymphocytes, such as changes in oncogenes or tumor suppressor genes, can drive the uncontrolled growth of cells. Environmental exposures, such as certain infections (e.g., Epstein-Barr virus, *Helicobacter pylori*, or HIV), and exposure to radiation or chemicals, can also play a role. Immunosuppressed individuals, such as those with organ transplants or autoimmune diseases, face a higher risk of developing lymphoma. Moreover, studies into the tumor microenvironment, which includes surrounding cells and signals that support tumor growth, are uncovering new targets for therapy [5, 6].

Recent scientific advances have revolutionized lymphoma treatment, offering patients better outcomes and quality of life. Traditional treatments, including chemotherapy and radiation, are now complemented by immunotherapies such as monoclonal antibodies (e.g., rituximab) and checkpoint inhibitors that enhance the immune system's ability to attack cancer cells. Additionally, CAR-T cell therapy, a cutting-edge approach that modifies a patient's own T cells to recognize and destroy lymphoma cells, has shown remarkable success in certain aggressive or relapsed cases. Ongoing research



into personalized medicine, targeting specific genetic and molecular features of lymphomas, continues to shape the future of treatment and offers hope for improved survival and fewer side effects [7].

Associated Mechanisms and Pathways

Lymphomas are driven by a complex interplay of genetic, molecular, and cellular mechanisms that disrupt the normal function of lymphocytes. The disease typically originates from B cells, T cells, or natural killer (NK) cells, which are critical components of the immune system. Dysregulation in these cells often begins with genetic mutations that activate oncogenes or inactivate tumor suppressor genes. One common mutation in B-cell lymphomas involves the BCL2 gene, which encodes a protein that prevents apoptosis, or programmed cell death. Overexpression of BCL2 leads to prolonged survival of malignant B cells. Similarly, translocations involving the MYC oncogene, particularly in aggressive lymphomas such as Burkitt lymphoma, drive rapid and uncontrolled cellular proliferation [8].

Epigenetic alterations also play a central role in lymphomagenesis. Modifications such as DNA methylation and histone acetylation can silence tumor suppressor genes or activate oncogenic pathways without altering the DNA sequence [9]. For instance, mutations in the EZH2 gene, a key regulator of chromatin structure, are frequently observed in follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). EZH2 mutations enhance lymphocyte survival and proliferation by modifying histones to repress genes involved in differentiation [10]. Advances in epigenetic research have led to the development of drugs targeting histone-modifying enzymes, offering potential therapeutic strategies for these malignancies.

Dysregulated signaling pathways are another hallmark of lymphoma development. The NF- κ B pathway, crucial for immune cell survival and inflammation, is often hyperactivated in lymphomas, especially in certain subtypes of DLBCL. Aberrations in this pathway, such as mutations in the CARD11 gene or alterations in upstream regulators like MYD88, result in constitutive activation of NF- κ B signaling, which promotes cell survival and resistance to apoptosis [11]. Similarly, the PI3K/AKT/mTOR pathway, involved in cell growth and metabolism, is frequently altered in lymphomas [12]. Targeted therapies that inhibit these pathways, such as PI3K inhibitors (e.g., idelalisib), have shown efficacy in treating certain types of NHL [13].

The tumor microenvironment significantly influences lymphoma progression and treatment resistance. Lymphoma cells interact with surrounding stromal cells, immune cells, and extracellular matrix components to create a supportive niche for their growth [14]. For example, in HL, Reed-Sternberg cells recruit an immunosuppressive environment by releasing cytokines such as IL-10 and TGF- β , which inhibit the activity of cytotoxic T cells and NK cells. This immune evasion mechanism has spurred the development of immune checkpoint inhibitors (e.g., PD-1 inhibitors like nivolumab) that restore the immune system's ability to attack tumor cells [15].

Advances in genomic and proteomic technologies have deepened our understanding of lymphoma biology and revealed actionable targets for therapy [16]. For instance, next-generation sequencing has identified recurrent mutations in genes involved in DNA repair, such as TP53 and ATM, which contribute to genomic instability and treatment resistance [17]. Similarly, studies on lymphoma stem cells—rare populations within tumors capable of self-renewal—have uncovered potential vulnerabilities [18]. Therapies targeting these pathways, such as inhibitors of DNA repair or agents that eliminate lymphoma stem cells, are under investigation [19]. The ongoing integration of molecular insights into clinical practice is shaping personalized medicine approaches, providing new hope for patients with both common and rare lymphoma subtypes.

Diagnostics and Advancements

The diagnosis of lymphoma begins with a thorough clinical evaluation, including a physical examination to identify swollen lymph nodes, spleen, or liver. Symptoms such as fever, night sweats, weight loss, and fatigue may prompt further investigation. Diagnostic confirmation requires a biopsy of the affected tissue, typically a lymph node, which is examined under a microscope to determine the presence of malignant lymphocytes and to classify the lymphoma subtype. This process is crucial because different subtypes have distinct prognosis and treatment approaches (Table 1) [20, 21].

Histopathological analysis

Histopathology remains the cornerstone of lymphoma diagnosis. A pathologist examines tissue samples to assess cellular morphology and identify features unique to specific subtypes [22]. For instance,

Table 1: Diagnostic approaches for lymphomas.

Diagnostic method	Principle	Applications	Examples/Markers	Advantages	Limitations
Histopathology	Microscopic examination of tissue morphology and structure.	Confirming lymphoma diagnosis and subtype.	Reed-Sternberg cells in HL; large atypical cells in DLBCL.	Gold standard for initial diagnosis.	Requires invasive biopsy; subjective interpretation.
Immunohistochemistry	Detection of specific cell surface markers using antibodies.	Subtyping and classification of lymphomas.	CD20 for B-cell lymphomas; CD3 for T-cell lymphomas.	Highly specific for identifying cell origin.	Requires expertise; limited multiplex capability.
Flow cytometry	Analysis of cell surface markers on individual cells in suspension.	Differentiating lymphoma subtypes; detecting MRD.	CD19, CD5, or CD10 for B-cell NHL subtypes.	Rapid and quantitative analysis.	Limited utility for solid tissue samples.
Molecular diagnostics	Detection of genetic mutations or translocations using PCR or FISH.	Identifying chromosomal abnormalities and mutations.	BCL2 or MYC translocations in aggressive NHL.	High sensitivity and specificity.	Expensive; not always available.
Genomic profiling	Comprehensive sequencing of DNA or RNA to detect mutations and expression patterns.	Identifying actionable mutations for targeted therapy.	TP53, MYD88, or EZH2 mutations.	Enables personalized medicine.	High cost; requires advanced infrastructure.
Liquid biopsy	Analysis of ctDNA or tumor markers in blood samples.	Monitoring treatment response; detecting MRD.	ctDNA; mutation tracking.	Minimally invasive and repeatable.	Sensitivity can be lower for early-stage disease.
Imaging	Visualization of tumor extent using radiological techniques.	Staging and assessing treatment response.	PET-CT (metabolic activity); MRI for soft tissues.	Non-invasive; provides detailed staging.	PET-CT exposes patients to radiation.
AI	AI algorithms analyze histopathological or imaging data to enhance accuracy.	Refining subtype diagnosis and prognosis prediction.	Radiomic patterns or digital pathology algorithms.	Improves diagnostic consistency and speed.	Requires robust data and validation.
Biomarker analysis	Detection of specific biological molecules linked to lymphoma.	Risk stratification and response prediction.	Cytokines (IL-10, IL-6), PD-L1 expression.	Offers prognostic insights.	May require validation for clinical use.



Reed-Sternberg cells are characteristic of HL, while DLBCL is marked by large, atypical lymphocytes. Immunohistochemistry further aids in diagnosis by detecting cell surface markers or antigens such as CD20 in B-cell lymphomas and CD3 in T-cell lymphomas [23]. This step is critical for confirming the lymphoma subtype.

Advanced imaging techniques

Imaging plays a vital role in staging and monitoring lymphoma. Techniques such as computed tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET) scans help determine the extent of disease spread [24]. PET-CT, in particular, is widely used for staging and evaluating treatment response by detecting metabolically active cancer cells using a radioactive glucose tracer [25]. These imaging tools provide detailed insights into tumor size, location, and activity, guiding treatment planning.

Flow cytometry and molecular diagnostics

Flow cytometry is an advanced technique used to analyze cell populations in blood, bone marrow, or lymph node samples. It identifies specific surface markers on lymphocytes, differentiating between B cells, T cells, and NK cells, and helps confirm the lymphoma subtype [26]. In addition, molecular diagnostics, including polymerase chain reaction (PCR) and fluorescence *in situ* hybridization (FISH), detect chromosomal abnormalities and genetic mutations such as translocations involving MYC or BCL2, which are critical in diagnosing aggressive lymphomas like Burkitt lymphoma [27].

Genomic and transcriptomic profiling

Recent advancements in next-generation sequencing have revolutionized lymphoma diagnostics by enabling comprehensive genomic and transcriptomic profiling. This technology identifies mutations, copy number alterations, and gene expression changes driving lymphomagenesis [28]. For example, mutations in TP53, MYD88, or EZH2 can indicate specific lymphoma subtypes and inform prognosis. Genomic profiling has also paved the way for personalized medicine by identifying actionable mutations that can be targeted with precision therapies [29].

Liquid biopsies

Liquid biopsies, a non-invasive diagnostic method, involve analyzing circulating tumor DNA (ctDNA) in the blood. This emerging technology offers a minimally invasive approach to detect genetic alterations, monitor disease progression, and evaluate treatment response [30]. Liquid biopsies are particularly useful for tracking residual disease after therapy and detecting early relapses [31]. Although still in its early stages for lymphoma, this technique has shown great promise in improving patient management.

Advances in AI and biomarkers

AI is increasingly being integrated into lymphoma diagnostics to enhance accuracy and efficiency. AI algorithms can analyze histopathological images, identify subtle patterns, and predict lymphoma subtypes with high precision [32]. Additionally, the discovery of novel biomarkers such as circulating microRNAs and immune signatures has the potential to refine diagnostic accuracy and predict treatment response [33]. These innovations are helping to bridge the gap between traditional diagnostics and cutting-edge technology.

In summary, despite these advancements, challenges remain in lymphoma diagnostics. Subtype heterogeneity, overlapping features,

and access to advanced technologies in low-resource settings can complicate diagnosis. Furthermore, integrating multi-omics data (genomics, proteomics, and metabolomics) into routine practice requires significant resources and expertise. Moving forward, research focused on developing cost-effective, accessible diagnostic tools and leveraging technologies like liquid biopsies and AI will be essential to improving global lymphoma care [34].

Treatment Approaches

The treatment of lymphomas involves a combination of approaches tailored to the specific subtype, stage, and patient factors. Traditional methods like chemotherapy and radiation therapy remain foundational, effectively targeting rapidly dividing cells and localized tumors [35]. Immunotherapies, including monoclonal antibodies and checkpoint inhibitors, harness the immune system to recognize and destroy lymphoma cells, while targeted therapies disrupt molecular pathways critical to cancer growth [35]. Cutting-edge treatments such as chimeric antigen receptors (CAR)-T cell therapy and hematopoietic stem cell transplants (HSCT) offer hope for aggressive or relapsed cases, though they come with significant risks and costs (Table 2) [35]. These advancements, combined with personalized medicine, are improving outcomes and transforming the management of lymphomas.

Chemotherapy

Chemotherapy uses cytotoxic drugs to kill rapidly dividing cells, including cancer cells. The principle lies in targeting cell cycle processes to inhibit proliferation and induce apoptosis. Chemotherapy is a cornerstone in lymphoma treatment, often used as a standalone therapy or in combination with other modalities. The CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone) is a standard for NHL (DLBCL), while ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) is commonly used for HL [36]. Chemotherapy lacks specificity, affecting healthy cells and causing side effects like immunosuppression, fatigue, and secondary malignancies. Resistance can also develop, necessitating alternative strategies [37].

Radiation therapy

Radiation therapy uses high-energy radiation to destroy cancer cells by damaging their DNA. It is often used for localized lymphomas or as consolidation therapy after chemotherapy [38, 39]. Advanced techniques like intensity-modulated radiation therapy allow precise targeting, minimizing harm to surrounding tissues. Radiation therapy for early-stage HL or localized extranodal NHL [40]. Limited utility for advanced or systemic disease. Long-term risks include secondary cancers and damage to nearby organs, such as the heart or lungs in chest irradiation [41].

Immunotherapy

Immunotherapy harnesses the patient's immune system to recognize and eliminate lymphoma cells. Monoclonal antibodies like rituximab target specific antigens (e.g., CD20 on B cells), marking them for destruction by immune cells [42]. Immune checkpoint inhibitors (e.g., nivolumab) block inhibitory signals like PD-1 to enhance T-cell activity [43]. Rituximab for B-cell NHL, nivolumab for relapsed/refractory HL [44]. Immunotherapy can cause immune-related adverse events, such as cytokine release syndrome, and is less effective in cases with extensive immune suppression or antigen escape [45].

Targeted therapy

Targeted therapies block specific molecular pathways critical



Table 2: Treatment approaches for lymphomas.

Treatment modality	Principle	Applications	Examples	Advantages	Limitations
Chemotherapy	Cytotoxic drugs target rapidly dividing cells.	Standard for most lymphomas; curative or palliative.	CHOP (NHL), ABVD (HL).	Effective for systemic disease.	Non-specific; significant side effects like immunosuppression.
Radiation therapy	High-energy radiation damages cancer cell DNA.	Localized lymphomas or consolidation therapy.	IMRT for HL, localized extranodal NHL.	Precise targeting of localized disease.	Not effective for widespread disease; risk of secondary malignancies.
Immunotherapy	Boosts immune system to recognize and destroy cancer cells.	Relapsed/refractory disease or maintenance therapy.	Rituximab (CD20+ NHL), nivolumab (HL).	High specificity; durable responses in some cases.	Immune-related adverse events; resistance can develop.
Targeted therapy	Blocks specific molecular pathways critical for lymphoma survival.	Subtypes with actionable mutations or targets.	Idelalisib (PI3K), brentuximab vedotin (CD30+ HL).	Personalized approach; less toxic than chemotherapy.	Limited to patients with specific targets; resistance risk.
CAR-T cell therapy	Genetically engineered T cells recognize lymphoma-specific antigens.	Relapsed/refractory aggressive lymphomas.	Axicabtagene ciloleucel (Yescarta).	High efficacy in refractory cases.	High cost; severe side effects like cytokine release syndrome.
HSCT	Replaces diseased bone marrow with healthy stem cells.	High-risk or relapsed lymphomas after initial therapy.	Autologous HSCT for NHL; allogeneic HSCT in severe cases.	Potentially curative for relapsed patients.	High toxicity; risks include infections and graft-versus-host disease.
Combination therapies	Combines multiple modalities to enhance efficacy.	Used for aggressive or resistant cases.	R-CHOP (rituximab + CHOP) for B-cell NHL.	Synergistic effects improve outcomes.	Increased side effects; complex management.
Immune checkpoint inhibitors	Blocks inhibitory signals in T cells, enhancing immune attack on tumors.	Relapsed/refractory HL.	Nivolumab (anti-PD-1).	Restores T-cell activity; effective in immune-suppressive environments.	May not work in patients without immune infiltration.
Experimental therapies	Novel approaches under investigation.	Clinical trials for various lymphoma subtypes.	Bispecific T-cell engagers, tumor vaccines.	Potential breakthroughs in treatment.	Limited availability; uncertain long-term efficacy.

for lymphoma growth and survival. These therapies exploit genetic or molecular vulnerabilities in lymphoma cells [46]. For instance, PI3K inhibitors (idelalisib) disrupt signaling pathways, while EZH2 inhibitors target epigenetic regulators [47]. Idelalisib for relapsed NHL, brentuximab vedotin for CD30+ HL [48]. Limited efficacy in some subtypes and the development of resistance. Targeted therapies may also have off-target effects, causing complications such as diarrhea or liver dysfunction [49].

CAR-T therapy

Cellular therapy involves genetically engineering a patient’s T cells to express CARs that specifically recognize and destroy lymphoma cells. CAR-T therapy is a breakthrough for aggressive and relapsed lymphomas [50]. Patients’ T cells are harvested, modified, and reinfused to target antigens like CD19 on lymphoma cells [51]. Axicabtagene ciloleucel (Yescarta) and tisagenlecleucel (Kymriah) for relapsed/refractory DLBCL [52]. High cost, logistical challenges, and severe side effects like cytokine release syndrome and neurotoxicity. It is primarily reserved for patients with relapsed or refractory disease [53].

HSCT

HSCT aims to replace the patient’s diseased or damaged bone marrow with healthy stem cells, enabling recovery after high-dose chemotherapy or radiation [54]. Autologous HSCT uses the patient’s own stem cells, while allogeneic HSCT involves donor cells. It is often used in aggressive or relapsed lymphomas [55]. Autologous HSCT for relapsed NHL or HL. Risk of graft-versus-host disease (for allogeneic HSCT), infections, and long recovery times. It is a highly intensive treatment, suitable only for selected patients [56].

In summary, each approach offers unique benefits and challenges, and the choice of therapy depends on lymphoma subtype, stage, patient health, and response to initial treatment. Increasingly, combinations of these treatments are employed to maximize efficacy while minimizing adverse effects.

Clinical Trials in Lymphoma Treatment

Clinical trials are essential for advancing the treatment of lymphomas, offering patients access to new therapies that may be more effective or have fewer side effects than standard treatments. These trials play a crucial role in determining the safety, efficacy, and optimal dosing of novel therapies, helping to improve overall survival rates and quality of life for lymphoma patients. As the field of oncology evolves, clinical trials also help identify the best treatment regimens for specific lymphoma subtypes and stages, thereby promoting personalized medicine [57, 58].

Lymphoma clinical trials can vary greatly in design and purpose, depending on the therapeutic approach being tested. Therapeutic trials focus on evaluating new drugs, combinations of therapies, or other treatments such as radiation or stem cell transplants. Prevention trials aim to identify interventions that could reduce the risk of developing lymphoma, while diagnostic and screening trials assess new ways of detecting or diagnosing lymphoma earlier. Supportive care trials focus on improving the quality of life for lymphoma patients by testing new symptom management strategies or supportive treatments [59].

Recent lymphoma clinical trials have focused on several promising therapies, particularly those targeting immune mechanisms. Immunotherapy trials explore the use of immune checkpoint inhibitors, such as nivolumab and pembrolizumab, which help the immune system recognize and attack lymphoma cells. CAR-T therapy is another cutting-edge treatment being tested in clinical trials for aggressive lymphomas, with trials investigating the efficacy of different CAR-T constructs. Additionally, trials are investigating the use of bispecific antibodies, which engage both T cells and tumor cells to enhance immune killing, and epigenetic modifiers, which aim to reprogram lymphoma cells for better treatment response. Ongoing clinical trials are pivotal in advancing lymphoma treatment, offering patients access to innovative therapies and contributing to the broader understanding of the disease (Table 3) [59].



Table 3: Clinical trials [59].

NCT ID	Study type	Trail phase	Title
NCT04224493	Interventional	III	A Study to Evaluate Tazemetostat Combined with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma
NCT02951156	Interventional	III	Avelumab in Combination Regimens that Include an Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
NCT02075840	Interventional	III	ALEX Study: A Randomized, Phase III Study Comparing Alectinib with Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Patients
NCT03959085	Interventional	III	Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients with High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
NCT05675410	Interventional	III	A Study to Compare Standard Therapy to Treat HL to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
NCT05605899	Interventional	III	Axicabtagene Ciloleuceel versus Standard of Care Therapy as First-Line Therapy in High-Risk Large B-Cell Lymphoma
NCT06356129	Interventional	III	Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus RCHOP in Participants with Previously Untreated High-risk Large B-cell Lymphoma
NCT02005471	Interventional	III	A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared with Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT04803201	Interventional	II	Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
NCT04947319	Interventional	II	Study of Tirabrutinib (ONO-4059) in Patients with Primary Central Nervous System Lymphoma (PROSPECT Study)
NCT03328078	Interventional	I/II	A Study of CA-4948 in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma
NCT04416984	Interventional	I/II	A Study to Evaluate the Safety and Effectiveness of ALLO-501A CAR T Cell Therapy in Adults with Relapsed/ Refractory Large B Cell Lymphoma
NCT04669171	Interventional	I/II	A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients with Indolent NHL

Challenges in Lymphoma Diagnosis and Treatment

One of the key challenges in lymphoma diagnosis is the complexity and diversity of the disease. Lymphoma encompasses a wide range of subtypes, each with distinct biological behaviors, clinical presentations, and prognoses. Diagnosing the specific subtype often requires a combination of techniques, including biopsy, histopathology, immunohistochemistry, and molecular testing. This process can be time-consuming and may require several rounds of testing, especially when rare or unusual forms of lymphoma are involved. Moreover, lymphoma often presents with symptoms that overlap with other diseases, leading to misdiagnosis or delayed diagnosis, which can impact treatment outcomes [60].

Detecting lymphoma at an early stage remains a challenge due to the lack of specific symptoms in the initial stages. Many patients experience vague symptoms such as fatigue, weight loss, or unexplained fever, which are common to several other conditions. As a result, lymphoma may be overlooked or misinterpreted as a less serious illness, delaying diagnosis and treatment. Moreover, current imaging and diagnostic techniques, although advanced, are not always sensitive enough to detect small or early-stage tumors, particularly in lymph nodes that are not easily accessible for biopsy. This issue highlights the need for better screening methods or biomarkers that can detect lymphoma earlier [61].

The treatment of lymphoma also presents significant challenges due to the heterogeneity of the disease. While treatments such as chemotherapy, immunotherapy, and stem cell transplants have significantly improved outcomes for many patients, they are not universally effective. Some lymphoma subtypes, particularly those that are rare or aggressive, may not respond well to standard treatments, requiring more personalized approaches. Additionally, relapsed or refractory lymphoma remains a significant issue, as tumors may develop resistance to therapies over time. This necessitates the continuous development of new drugs and treatment combinations, as well as better strategies for overcoming treatment resistance.

The side effects associated with lymphoma treatment, particularly chemotherapy and radiation therapy, pose another challenge. These treatments can cause significant toxicities, including

immunosuppression, organ damage, and increased susceptibility to infections, which compromise the patient's overall health. For patients with already compromised immune systems, such as those undergoing stem cell transplants, the risks of severe complications increase. While newer therapies such as immunotherapies and targeted treatments aim to reduce side effects, they also come with their own set of challenges, including immune-related adverse events and high treatment costs. Balancing treatment efficacy with the potential for long-term side effects is a critical consideration in lymphoma management.

Conclusion and Future Prospects

Lymphoma remains a complex and multifaceted group of cancers that presents significant challenges in both diagnosis and treatment. Despite advancements in therapeutic strategies such as chemotherapy, immunotherapy, targeted therapies, and stem cell transplants, the variability in disease subtypes, relapse rates, and treatment resistance continues to complicate management. Early detection remains elusive, with symptoms often overlapping with other illnesses, and the diagnosis is frequently delayed, potentially hindering effective treatment. However, the growing understanding of lymphoma's molecular and genetic underpinnings offers hope for more personalized and effective interventions in the future.

The future of lymphoma treatment is increasingly focused on precision medicine, which tailors therapies based on an individual's genetic profile, tumor characteristics, and specific molecular pathways. Advances in immunotherapies, such as CAR-T cell therapies and immune checkpoint inhibitors, have already demonstrated remarkable success in relapsed or refractory lymphomas, and ongoing research aims to refine these treatments for broader applications. Additionally, the exploration of targeted therapies that address specific mutations or signaling pathways offers promising avenues for improving outcomes while minimizing toxicity. These developments could pave the way for more effective, less invasive treatments with fewer side effects.

Future prospects for lymphoma diagnosis include the development of more sensitive, non-invasive screening methods, such as liquid biopsy, which can detect tumor DNA or RNA in blood samples. This approach could allow for earlier detection of lymphoma and better monitoring of disease progression or response to treatment. Enhanced



imaging techniques, as well as AI-driven diagnostic tools, are also on the horizon, with the potential to improve the accuracy of lymphoma staging and help identify smaller, clinically significant lesions that might otherwise be missed. These innovations could significantly improve the overall prognosis for lymphoma patients by enabling timely intervention.

The global collaboration between researchers, clinicians, and pharmaceutical companies is crucial for accelerating lymphoma treatment innovations. Large-scale clinical trials, especially those incorporating real-world data and adaptive trial designs, can speed up the development of new therapies and allow for faster approval of promising treatments. Furthermore, international efforts to improve access to these therapies in underserved regions could lead to more equitable outcomes for lymphoma patients worldwide. As the field continues to evolve, the integration of cutting-edge research, advanced technologies, and global partnerships will likely transform the landscape of lymphoma care, offering patients better survival rates, fewer side effects, and improved quality of life.

Acknowledgements

None.

Conflict of Interest

None.

References

1. Lymphoma. Mayo Clinic. [<https://www.mayoclinic.org/diseases-conditions/lymphoma/symptoms-causes/syc-20352638>] [Accessed March 29, 2025]
2. What is Hodgkin Lymphoma? Canadian Cancer Society. [<https://cancer.ca/en/cancer-information/cancer-types/hodgkin-lymphoma/what-is-hodgkin-lymphoma>] [Accessed March 29, 2025]
3. What is Non-Hodgkin Lymphoma? Canadian Cancer Society. [<https://cancer.ca/en/cancer-information/cancer-types/non-hodgkin-lymphoma/what-is-non-hodgkin-lymphoma>] [Accessed March 29, 2025]
4. Global Cancer Observatory. [<https://gco.iarc.fr/en>] [Accessed March 29, 2025]
5. Causes and Risk Factors for Lymphoma. [<https://lymphoma-action.org.uk/about-lymphoma-what-lymphoma/causes-and-risk-factors-lymphoma>] [Accessed March 29, 2025]
6. Lymphoma Causes and Risk Factors. [<https://www.mylmphomateam.com/resources/what-causes-lymphoma>] [Accessed March 29, 2025]
7. Flowers CR, Armitage JO (2010) A decade of progress in lymphoma: advances and continuing challenges. *Clin Lymphoma Myeloma Leuk* 10: 414-423. <https://doi.org/10.3816/clml.2010.n.086>
8. Weniger MA, Küppers R (2021) Molecular biology of Hodgkin lymphoma. *Leukemia* 35: 968-981. <https://doi.org/10.1038/s41375-021-01204-6>
9. Zhang P, Zhang M (2020) Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma. *Clin Epigenetics* 12: 1-17. <https://doi.org/10.1186/s13148-020-00962-x>
10. Gan L, Yang Y, Li Q, Feng Y, Liu T, et al. (2018) Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. *Biomark Res* 6: 1-10. <https://doi.org/10.1186/s40364-018-0122-2>
11. Pasqualucci L, Klein U (2022) NF- κ B mutations in germinal center B-cell lymphomas: relation to NF- κ B function in normal B cells. *Biomedicines* 10: 2450. <https://doi.org/10.3390/biomedicines10102450>
12. Westin JR (2014) Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma. *Clin Lymphoma Myeloma Leuk* 14: 335-342. <https://doi.org/10.1016/j.clml.2014.01.007>
13. Lampson BL, Brown JR (2017) PI3K δ -selective and PI3K α/δ -combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. *Expert Opin Investig Drugs* 26: 1267-1279. <https://doi.org/10.1080/13543784.2017.1384815>
14. Upadhyay R, Hammerich L, Peng P, Brown B, Merad M, et al. (2015) Lymphoma:

- immune evasion strategies. *Cancers* 7: 736-762. <https://doi.org/10.3390/cancers7020736>
15. Menéndez V, Solórzano JL, Fernández S, Montalbán C, García JF (2022) The Hodgkin lymphoma immune microenvironment: turning bad news into good. *Cancers* 14: 1360. <https://doi.org/10.3390/cancers14051360>
16. Rosenquist R, Bernard E, Erkers T, Scott DW, Itzykson R, et al. (2023) Novel precision medicine approaches and treatment strategies in hematological malignancies. *J Intern Med* 294: 413-436. <https://doi.org/10.1111/joim.13697>
17. Jurkovicova D, Neophytou CM, Gašparović AČ, Gonçalves AC (2022) DNA damage response in cancer therapy and resistance: challenges and opportunities. *Int J Mol Sci* 23: 14672. <https://doi.org/10.3390/ijms232314672>
18. Mann Z, Sengar M, Verma YK, Rajalingam R, Raghav PK (2022) Hematopoietic stem cell factors: their functional role in self-renewal and clinical aspects. *Front Cell Dev Biol* 10: 1-22. <https://doi.org/10.3389/fcell.2022.664261>
19. Alhmoud JF, Mustafa AG, Malki MI (2020) Targeting DNA repair pathways in hematological malignancies. *Int J Mol Sci* 21: 7365. <https://doi.org/10.3390/ijms21197365>
20. Lymphoma. Radiology Information for Patients. [<https://www.radiologyinfo.org/en/info/lymphoma>] [Accessed March 29, 2025]
21. Sethi S, Epstein-Peterson Z, Kumar A, Ho C (2021) Current knowledge in genetics, molecular diagnostic tools, and treatments for mantle cell lymphomas. *Front Oncol* 11: 1-14. <https://doi.org/10.3389/fonc.2021.739441>
22. Kansal R (2023) Diagnosis and molecular pathology of lymphoblastic leukemias and lymphomas in the era of genomics and precision medicine: historical evolution and current concepts—part 3: mature leukemias/lymphomas. *Lymphatics* 1: 155-219.
23. Parente P, Zanelli M, Sanguedolce F, Mastracci L, Graziano P (2020) Hodgkin Reed-Sternberg-like cells in non-Hodgkin lymphoma. *Diagnostics* 10: 1019. <https://doi.org/10.3390/diagnostics10121019>
24. Kwee TC, Kwee RM, Nievesstein RA (2008) Imaging in staging of malignant lymphoma: a systematic review. *Blood* 111: 504-516. <https://doi.org/10.1182/blood-2007-07-101899>
25. Jin P, Li J, Meng Y, Wu L, Bai M, et al. (2021) PET/CT metabolic patterns in systemic immune activation: a new perspective on the assessment of immunotherapy response and efficacy. *Cancer Lett* 520: 91-99. <https://doi.org/10.1016/j.canlet.2021.06.028>
26. Tembhare PR, Chatterjee G, Chaturvedi A, Dasgupta N, Khanka T, et al. (2022) Critical role of flow cytometric immunophenotyping in the diagnosis, subtyping, and staging of T-cell/NK-cell non-Hodgkin's lymphoma in real-world practice: a study of 232 cases from a tertiary cancer center in India. *Front Oncol* 12: 1-22. <https://doi.org/10.3389/fonc.2022.779230>
27. Loo EY (2020) Follicular and mantle cell lymphomas: technical and interpretive considerations; karyotyping, FISH, chromosomal microarray, sequencing, B-cell clonality, minimal residual disease. In *Follicular Lymphoma and Mantle Cell Lymphoma*.
28. Kansal R (2023) Diagnosis and molecular pathology of lymphoblastic leukemias and lymphomas in the era of genomics and precision medicine: historical evolution and current concepts—part 2: B-/T-cell acute lymphoblastic leukemias. *Lymphatics* 1: 118-154. <https://doi.org/10.3390/lymphatics1020011>
29. Bühler MM, Martin-Subero JI, Pan-Hammarström Q, Campo E, Rosenquist R (2022) Towards precision medicine in lymphoid malignancies. *J Intern Med* 292: 221-242. <https://doi.org/10.1111/joim.13423>
30. Openshaw MR, McVeigh TP (2020) Non-invasive technology advances in cancer—a review of the advances in the liquid biopsy for endometrial and ovarian cancers. *Front Digit Health* 2: 1-15. <https://doi.org/10.3389/fdgh.2020.573010>
31. Heidrich I, Deitert B, Werner S, Pantel K (2023) Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors. *Cancer Metastasis Rev* 42: 161-182. <https://doi.org/10.1007/s10555-022-10075-x>
32. Hasanabadi S, Aghamiri SMR, Abin AA, Abdollahi H, Arabi H, et al. (2024) Enhancing lymphoma diagnosis, treatment, and follow-up using 18F-FDG PET/CT imaging: Contribution of artificial intelligence and radiomics analysis. *Cancers* 6: 3511. <https://doi.org/10.3390/cancers16203511>
33. Aswathy R, Chalos VA, Suganya K, Sumathi S (2024) Advancing miRNA cancer research through artificial intelligence: from biomarker discovery to therapeutic targeting. *Med Oncol* 42: 30. <https://doi.org/10.1007/s12032-024-02579-z>
34. Wei L, Niraula D, Gates ED, Fu J, Luo Y, et al. (2023) Artificial intelligence (AI) and



- machine learning (ML) in precision oncology: a review on enhancing discoverability through multiomics integration. *Br J Radiol* 96: 1-13. <https://doi.org/10.1259/bjr.20230211>
35. Treatment Planning and Options. Lymphoma Research Foundation. [<https://lymphoma.org/understanding-lymphoma/treatment-planning-and-options/treatments>] [Accessed March 29, 2025]
36. Mahajan S, Aalhathe M, Guru SK, Singh PK (2022) Nanomedicine as a magic bullet for combating lymphoma. *J Control Release* 347: 211-236. <https://doi.org/10.1016/j.jconrel.2022.05.002>
37. Farhana A, Alsrhani A, Khan YS, Rasheed Z (2023) Cancer bioenergetics and tumor microenvironments-Enhancing chemotherapeutics and targeting resistant niches through nanosystems. *Cancers* 15: 3836. <https://doi.org/10.3390/cancers15153836>
38. Le Reun E, Foray N (2023) Low-dose radiation therapy (LDRT) against cancer and inflammatory or degenerative diseases: three parallel stories with a common molecular mechanism involving the nucleoshuttling of the ATM protein? *Cancers* 15: 1482. <https://doi.org/10.3390/cancers15051482>
39. Chambial P, Bhukya PL, Bahl V, Thakur N (2024) Conventional methods of cancer therapy. In *Nanoparticles in Cancer Theranostics*. CRC Press, pp 173-195.
40. Wirth A, Mikhaeel NG, Aleman BM, Pinnix CC, Constine LS, et al. (2020) Involved site radiation therapy in adult lymphomas: an overview of international lymphoma radiation oncology group guidelines. *Int J Radiat Oncol Biol Phys* 107: 909-933. <https://doi.org/10.1016/j.ijrobp.2020.03.019>
41. Thariat J, Little MP, Zablotska LB, Samson P, O'Banion MK, et al. (2024) Radiotherapy for non-cancer diseases: benefits and long-term risks. *Int J Radiat Biol* 100: 505-526. <https://doi.org/10.1080/09553002.2023.2295966>
42. Raghani NR, Chorawala MR, Mahadik M, Patel RB, Prajapati BG, et al (2024) Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies. *Med Oncol* 41: 51. <https://doi.org/10.1007/s12032-023-02280-7>
43. Liu J, Chen Z, Li Y, Zhao W, Wu J, et al. (2021) PD-1/PD-L1 checkpoint inhibitors in tumor immunotherapy. *Front Pharmacol* 12: 1-8. <https://doi.org/10.3389/fphar.2021.731798>
44. Randall MP, Spinner MA (2023) Optimizing treatment for relapsed/refractory classic Hodgkin lymphoma in the era of immunotherapy. *Cancers* 15: 4509. <https://doi.org/10.3390/cancers15184509>
45. Casagrande S, Sopetto GB, Bertalot G, Bortolotti R, Racanelli V, et al. (2024) Immune-related adverse events due to cancer immunotherapy: immune mechanisms and clinical manifestations. *Cancers* 16: 1440. <https://doi.org/10.3390/cancers16071440>
46. Roschewski M, Hodson DJ (2024) Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy. *Haematologica* 109: 388-400. <https://doi.org/10.3324/haematol.2021.278613>
47. Julia E, Salles G (2021) EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma. *Future Oncol* 17: 2127-2140. <https://doi.org/10.2217/fon-2020-1244>
48. Varma G, Goldstein J, Advani RH (2023) Novel agents in relapsed/refractory diffuse large B-cell lymphoma. *Hematol Oncol* 41: 92-106. <https://doi.org/10.1002/hon.3143>
49. Makita S, Hosoba R, Tobinai K (2020) Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma. *Expert Opin Drug Saf* 19: 1105-1120. <https://doi.org/10.1080/14740338.2020.1802424>
50. De Bousser E, Callewaert N, Festjens N (2021) T cell engaging immunotherapies, highlighting chimeric antigen receptor (CAR) T cell therapy. *Cancers* 13: 6067. <https://doi.org/10.3390/cancers13236067>
51. Gambella M, Carlomagno S, Raiola AM, Giannoni L, Ghiggi C, et al. (2022) CD19-targeted immunotherapies for diffuse large B-cell lymphoma. *Front Immunol* 13: 1-9. <https://doi.org/10.3389/fimmu.2022.837457>
52. Mohty M, Dulery R, Gauthier J, Malard F, Brissot E, et al. (2020) CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. *Bone Marrow Transplant* 55: 1525-1532. <https://doi.org/10.1038/s41409-020-0892-7>
53. Freyer CW, Porter DL (2020) Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. *J Allergy Clin Immunol* 146: 940-948. <https://doi.org/10.1016/j.jaci.2020.07.025>
54. Chander V, Gangenahalli G (2020) Emerging strategies for enhancing the homing of hematopoietic stem cells to the bone marrow after transplantation. *Exp Cell Res* 390: 111954. <https://doi.org/10.1016/j.yexcr.2020.111954>
55. Sandler RD, Carter S, Kaur H, Francis S, Tattersall RS, et al. (2020) Haemophagocytic lymphohistiocytosis (HLH) following allogeneic haematopoietic stem cell transplantation (HSCT)-time to reappraise with modern diagnostic and treatment strategies?. *Bone Marrow Transplant* 55: 307-316. <https://doi.org/10.1038/s41409-019-0637-7>
56. Veilleux O, Claveau JS, Alaoui H, Serroukh Y, Ahmad I, et al. (2022) Real-world outcomes of autologous and allogeneic hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma in the era of novel therapies: a Canadian perspective. *Transplant Cell Ther* 28: 145-151. <https://doi.org/10.1016/j.jtct.2021.12.005>
57. Fred Hutch Cancer Center. Lymphoma Research. [<https://www.fredhutch.org/en/diseases/hodgkin-lymphoma/lymphoma-research.html>] [Accessed March 29, 2025]
58. MOFFITT Cancer Center. Lymphoma Clinical Trials. [<https://www.moffitt.org/cancers/lymphomas-hodgkin-and-non-hodgkin/treatment/clinical-trials>] [Accessed March 29, 2025]
59. Mayo Clinic. Lymphoma Clinical Trials. [<https://www.mayo.edu/research/clinical-trials/diseases-conditions/lymphoma>]. [Accessed March 29, 2025]
60. Takahara T, Satou A, Tsuzuki T, Nakamura S (2022) Hodgkin lymphoma: biology and differential diagnostic problem. *Diagnostics* 12: 1507. <https://doi.org/10.3390/diagnostics12061507>
61. Medical News Today. What are the Early Signs and Symptoms of Lymphoma? [<https://www.medicalnewstoday.com/articles/early-signs-of-lymphoma>] [Accessed March 29, 2025]